Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T15:01:39.937Z.
Calculation as of: 2026-10-06T15:01:39.937Z.
Quote observation: 2026-10-06T15:00:33.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 1148a26bf5d8a77c385830e28adfe1a3226667ff180e3eaa52d15dba3998f7d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Bluejay Diagnostics, Inc.
Market Cap
$838118.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$835190.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$870069.00
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
Price/FCF Ratio
N/A
TTM Avg
60791.74
3Y Avg
60791.74
5Y Avg
60791.74
Market Cap
$1.11M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Bluejay Diagnostics, Inc. (BJDX) | $838118.00 | N/A | N/A | N/A | N/A |
| Decoy Therapeutics Inc. (DCOY)vs › | $835190.00 | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $865985.00 | N/A | N/A | N/A | N/A |
| Bone Biologics Corporation (BBLG)vs › | $870069.00 | N/A | N/A | N/A | N/A |
| CDT Equity Inc. (CDT)vs › | $671998.00 | N/A | 0.46 | 0.46 | 0.46 |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 60791.74 | 60791.74 | 60791.74 |
| HCW Biologics Inc. (HCWB)vs › | $560606.00 | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.08M | N/A | N/A | N/A | N/A |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.18M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
